APO Research
Talk to an analyst

APO RESEARCH · REPORT

Depression Drugs

Depression is a mental health issue. It’s a condition that starts most often in early adulthood. It’s also more common in women. However, anyone at any age may suffer from depression. Depression affects the brain, so drugs that work in the brain may offer hope. Common antidepressants may help ease your symptoms, but there are many other options as well. Each drug used to treat depression works by balancing certain chemicals in your brain called neurotransmitters. Depression Drugs is drugs used for Depression.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Depression is a mental health issue. It’s a condition that starts most often in early adulthood. It’s also more common in women. However, anyone at any age may suffer from depression. Depression affects the brain, so drugs that work in the brain may offer hope. Common antidepressants may help ease your symptoms, but there are many other options as well. Each drug used to treat depression works by balancing certain chemicals in your brain called neurotransmitters. Depression Drugs is drugs used for Depression.

Selected research

Market Outlook & Growth Opportunities

Global Depression Drugs Market Outlook and Growth Opportunities 2026

22 December 2025197 pages

Choose your research edition.

Industry ResearchDepression Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Depression Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Depression Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Depression Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Depression Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

Depression is a mental health issue. It’s a condition that starts most often in early adulthood. It’s also more common in women. However, anyone at any age may suffer from depression. Depression affects the brain, so drugs that work in the brain may offer hope. Common antidepressants may help ease your symptoms, but there are many other options as well. Each drug used to treat depression works by balancing certain chemicals in your brain called neurotransmitters. Depression Drugs is drugs used for Depression.

Global Depression Drugs key players include Intellipharmaceutics, Pfizer, Eli Lilly, Astrazeneca, Lundbeck, etc. Global top five manufacturers hold a share over 35%.

North America is the largest market, with a share over 40%, followed by Europe and Asia-Pacific, both have a share about 50%.

Read the full market overview

In terms of product, SSRIs is the largest segment, with a share over 45%. And in terms of application, the largest application is Hospitals, followed by Clinics, etc.

This report provides an overview of the global Depression Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Depression Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Depression Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Depression Drugs market.

Depression Drugs Segment by Company

Intellipharmaceutics

Pfizer

Eli Lilly

Astrazeneca

Lundbeck

Allergan

GSK

Otsuka Pharmaceutical

Takeda

NHU Group

Shionogi

APOTEX

Kanghong Pharma

HUAHAI

Depression Drugs Segment by Type

SSRIs

SNRIs

Others

Depression Drugs Segment by Application

Hospitals

Clinics

Others

Depression Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Depression Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Depression Drugs key companies, revenue, market share, and recent developments.

3. To split the Depression Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Depression Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Depression Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Depression Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Depression Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Depression Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Depression Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Depression Drugs industry.

Chapter 3: Detailed analysis of Depression Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Depression Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Depression Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Depression Drugs Industry Trends Table 2. Depression Drugs Industry Drivers Table 3. Depression Drugs Industry Opportunities and Challenges Table 4. Depression Drugs Industry Restraints Table 5. Global Depression Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Depression Drugs Revenue Share by Company (2021-2026) Table 7. Global Depression Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Depression Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Depression Drugs Company, Product Type & Application Table 10. Global Depression Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Depression Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of SSRIs Table 15. Significant Companies of SNRIs Table 16. Significant Companies of Others Table 17. Global Depression Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Depression Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Depression Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Depression Drugs Sales Value Share by Type (2021-2026) Table 21. Global Depression Drugs Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospitals Table 23. Significant Companies of Clinics Table 24. Significant Companies of Others Table 25. Global Depression Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Depression Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Depression Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Depression Drugs Sales Value Share by Application (2021-2026) Table 29. Global Depression Drugs Sales Value Share by Application (2027-2032) Table 30. Global Depression Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Depression Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Depression Drugs Sales Value Share by Region (2021-2026) Table 33. Global Depression Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Depression Drugs Sales Value Share by Region (2027-2032) Table 35. Global Depression Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Depression Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Depression Drugs Sales Value Market Share by Country (2021-2026) Table 38. Global Depression Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Depression Drugs Sales Value Market Share by Country (2027-2032) Table 40. Intellipharmaceutics Company Information Table 41. Intellipharmaceutics Business Overview Table 42. Intellipharmaceutics Depression Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Intellipharmaceutics Depression Drugs Product Portfolio Table 44. Intellipharmaceutics Recent Development Table 45. Pfizer Company Information Table 46. Pfizer Business Overview Table 47. Pfizer Depression Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Pfizer Depression Drugs Product Portfolio Table 49. Pfizer Recent Development Table 50. Eli Lilly Company Information Table 51. Eli Lilly Business Overview Table 52. Eli Lilly Depression Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Eli Lilly Depression Drugs Product Portfolio Table 54. Eli Lilly Recent Development Table 55. Astrazeneca Company Information Table 56. Astrazeneca Business Overview Table 57. Astrazeneca Depression Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Astrazeneca Depression Drugs Product Portfolio Table 59. Astrazeneca Recent Development Table 60. Lundbeck Company Information Table 61. Lundbeck Business Overview Table 62. Lundbeck Depression Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Lundbeck Depression Drugs Product Portfolio Table 64. Lundbeck Recent Development Table 65. Allergan Company Information Table 66. Allergan Business Overview Table 67. Allergan Depression Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Allergan Depression Drugs Product Portfolio Table 69. Allergan Recent Development Table 70. GSK Company Information Table 71. GSK Business Overview Table 72. GSK Depression Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. GSK Depression Drugs Product Portfolio Table 74. GSK Recent Development Table 75. Otsuka Pharmaceutical Company Information Table 76. Otsuka Pharmaceutical Business Overview Table 77. Otsuka Pharmaceutical Depression Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Otsuka Pharmaceutical Depression Drugs Product Portfolio Table 79. Otsuka Pharmaceutical Recent Development Table 80. Takeda Company Information Table 81. Takeda Business Overview Table 82. Takeda Depression Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Takeda Depression Drugs Product Portfolio Table 84. Takeda Recent Development Table 85. NHU Group Company Information Table 86. NHU Group Business Overview Table 87. NHU Group Depression Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. NHU Group Depression Drugs Product Portfolio Table 89. NHU Group Recent Development Table 90. Shionogi Company Information Table 91. Shionogi Business Overview Table 92. Shionogi Depression Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 93. Shionogi Depression Drugs Product Portfolio Table 94. Shionogi Recent Development Table 95. APOTEX Company Information Table 96. APOTEX Business Overview Table 97. APOTEX Depression Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 98. APOTEX Depression Drugs Product Portfolio Table 99. APOTEX Recent Development Table 100. Kanghong Pharma Company Information Table 101. Kanghong Pharma Business Overview Table 102. Kanghong Pharma Depression Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 103. Kanghong Pharma Depression Drugs Product Portfolio Table 104. Kanghong Pharma Recent Development Table 105. HUAHAI Company Information Table 106. HUAHAI Business Overview Table 107. HUAHAI Depression Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 108. HUAHAI Depression Drugs Product Portfolio Table 109. HUAHAI Recent Development Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Depression Drugs Product Image Figure 2. Global Depression Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Depression Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Depression Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. SSRIs Image Figure 8. SNRIs Image Figure 9. Others Image Figure 10. Global Depression Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Depression Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Depression Drugs Sales Value Share by Type (2021-2032) Figure 13. Hospitals Image Figure 14. Clinics Image Figure 15. Others Image Figure 16. Global Depression Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Depression Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Depression Drugs Sales Value Share by Application (2021-2032) Figure 19. Global Depression Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Depression Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Depression Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. North America Depression Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Depression Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Depression Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Depression Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Depression Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Depression Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. South America Depression Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Depression Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Depression Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Depression Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Depression Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Depression Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • SSRIs
  • SNRIs
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Intellipharmaceutics
  • Pfizer
  • Eli Lilly
  • Astrazeneca
  • Lundbeck
  • Allergan
  • GSK
  • Otsuka Pharmaceutical
  • Takeda
  • NHU Group
  • Shionogi
  • APOTEX
  • Kanghong Pharma
  • HUAHAI

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Depression Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Depression Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Depression Drugs Market Dynamics
  1. 2.1 Depression Drugs Industry Trends
  2. 2.2 Depression Drugs Industry Drivers
  3. 2.3 Depression Drugs Industry Opportunities and Challenges
  4. 2.4 Depression Drugs Industry Restraints
3 Depression Drugs Market by Company
  1. 3.1 Global Depression Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Depression Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Depression Drugs Company Ranking (2024-2026)
  4. 3.4 Global Depression Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Depression Drugs Company Product Type and Application
  6. 3.6 Global Depression Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Depression Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Depression Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Depression Drugs Market by Type
  1. 4.1 Depression Drugs Type Introduction
  2. 4.1.1 SSRIs
  3. 4.1.2 SNRIs
  4. 4.1.3 Others
  5. 4.2 Global Depression Drugs Sales Value by Type
  6. 4.2.1 Global Depression Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Depression Drugs Sales Value by Type (2021-2032)
  8. 4.2.3 Global Depression Drugs Sales Value Share by Type (2021-2032)
5 Depression Drugs Market by Application
  1. 5.1 Depression Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Depression Drugs Sales Value by Application
  6. 5.2.1 Global Depression Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Depression Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Depression Drugs Sales Value Share by Application (2021-2032)
6 Depression Drugs Regional Value Analysis
  1. 6.1 Global Depression Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Depression Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Depression Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Depression Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Depression Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Depression Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Depression Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Depression Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Depression Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Depression Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Depression Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Depression Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Depression Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Depression Drugs Sales Value Share by Country, 2025 VS 2032
7 Depression Drugs Country-level Value Analysis
  1. 7.1 Global Depression Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Depression Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Depression Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Depression Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Depression Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Depression Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Depression Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Depression Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Depression Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Depression Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Depression Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Depression Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Depression Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Depression Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Depression Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Depression Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Depression Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Depression Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Depression Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Depression Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Depression Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Depression Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Depression Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Depression Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Depression Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Depression Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Depression Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Depression Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Depression Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Depression Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Depression Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Depression Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Depression Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Depression Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Depression Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Depression Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Depression Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Depression Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Depression Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Depression Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Depression Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Depression Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Depression Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Depression Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Depression Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Depression Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Depression Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Depression Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Depression Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Depression Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Depression Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Depression Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Depression Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Depression Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Depression Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Depression Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Depression Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Depression Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Depression Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Depression Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Depression Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Depression Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Depression Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Depression Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Depression Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Depression Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Depression Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Depression Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Depression Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Depression Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Depression Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Depression Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Depression Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Depression Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Depression Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Depression Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Depression Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Depression Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Depression Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Depression Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Depression Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Depression Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Depression Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Depression Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Depression Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Depression Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Depression Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Depression Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Intellipharmaceutics
  2. 8.1.1 Intellipharmaceutics Company Information
  3. 8.1.2 Intellipharmaceutics Business Overview
  4. 8.1.3 Intellipharmaceutics Depression Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Intellipharmaceutics Depression Drugs Product Portfolio
  6. 8.1.5 Intellipharmaceutics Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Depression Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Depression Drugs Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Depression Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Depression Drugs Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Astrazeneca
  20. 8.4.1 Astrazeneca Company Information
  21. 8.4.2 Astrazeneca Business Overview
  22. 8.4.3 Astrazeneca Depression Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Astrazeneca Depression Drugs Product Portfolio
  24. 8.4.5 Astrazeneca Recent Developments
  25. 8.5 Lundbeck
  26. 8.5.1 Lundbeck Company Information
  27. 8.5.2 Lundbeck Business Overview
  28. 8.5.3 Lundbeck Depression Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lundbeck Depression Drugs Product Portfolio
  30. 8.5.5 Lundbeck Recent Developments
  31. 8.6 Allergan
  32. 8.6.1 Allergan Company Information
  33. 8.6.2 Allergan Business Overview
  34. 8.6.3 Allergan Depression Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Allergan Depression Drugs Product Portfolio
  36. 8.6.5 Allergan Recent Developments
  37. 8.7 GSK
  38. 8.7.1 GSK Company Information
  39. 8.7.2 GSK Business Overview
  40. 8.7.3 GSK Depression Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GSK Depression Drugs Product Portfolio
  42. 8.7.5 GSK Recent Developments
  43. 8.8 Otsuka Pharmaceutical
  44. 8.8.1 Otsuka Pharmaceutical Company Information
  45. 8.8.2 Otsuka Pharmaceutical Business Overview
  46. 8.8.3 Otsuka Pharmaceutical Depression Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Otsuka Pharmaceutical Depression Drugs Product Portfolio
  48. 8.8.5 Otsuka Pharmaceutical Recent Developments
  49. 8.9 Takeda
  50. 8.9.1 Takeda Company Information
  51. 8.9.2 Takeda Business Overview
  52. 8.9.3 Takeda Depression Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Takeda Depression Drugs Product Portfolio
  54. 8.9.5 Takeda Recent Developments
  55. 8.10 NHU Group
  56. 8.10.1 NHU Group Company Information
  57. 8.10.2 NHU Group Business Overview
  58. 8.10.3 NHU Group Depression Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 NHU Group Depression Drugs Product Portfolio
  60. 8.10.5 NHU Group Recent Developments
  61. 8.11 Shionogi
  62. 8.11.1 Shionogi Company Information
  63. 8.11.2 Shionogi Business Overview
  64. 8.11.3 Shionogi Depression Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Shionogi Depression Drugs Product Portfolio
  66. 8.11.5 Shionogi Recent Developments
  67. 8.12 APOTEX
  68. 8.12.1 APOTEX Company Information
  69. 8.12.2 APOTEX Business Overview
  70. 8.12.3 APOTEX Depression Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 APOTEX Depression Drugs Product Portfolio
  72. 8.12.5 APOTEX Recent Developments
  73. 8.13 Kanghong Pharma
  74. 8.13.1 Kanghong Pharma Company Information
  75. 8.13.2 Kanghong Pharma Business Overview
  76. 8.13.3 Kanghong Pharma Depression Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Kanghong Pharma Depression Drugs Product Portfolio
  78. 8.13.5 Kanghong Pharma Recent Developments
  79. 8.14 HUAHAI
  80. 8.14.1 HUAHAI Company Information
  81. 8.14.2 HUAHAI Business Overview
  82. 8.14.3 HUAHAI Depression Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 HUAHAI Depression Drugs Product Portfolio
  84. 8.14.5 HUAHAI Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst